Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      AVAILABLE
      MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
      Description

      The purpose of this Expanded Access Program (EAP) is to allow use of the investigational therapeutic agent, MNPR-101-PCTA-177Lu, for treatment of urokinase plasminogen activator receptor (uPAR)-positive solid tumors identified via positron emission tomography / computed tomography (PET/CT) with investigational imaging agent MNPR-101-DFO\*-89Zr.

      Conditions
      CancerSolid TumorSolid Tumor CancerOncologyuPAR-positive Solid TumorUrokinase Plasminogen Activator Receptor-positive Solid Tumor
      Talk to us